Zimmerman R L, Bagley D, Hawthorne C, Bibbo M
Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia 19104-2699, USA.
Urology. 1998 Jun;51(6):956-8. doi: 10.1016/s0090-4295(98)00115-0.
The Bard BTA test has been shown in early studies to be useful in diagnosing transitional cell carcinoma (TCC) of the bladder. However, the utility of this test has not been evaluated for TCC of the upper urinary tract. We therefore evaluated the clinical utility of the BTA test for upper urinary TCC.
We tested 71 specimens from the ureter and/or renal pelvis in 22 patients with a history or clinical suspicion for TCC and 9 patients with benign disorders.
When compared to cytologic diagnoses, BTA had a sensitivity of 65%, a specificity of 40% (when correlated with clinical history), a false-positive rate of 33%, and a false-negative rate of 62%. The test had a positive predictive value of 83% and a negative predictive value of 32%.
The BTA does not have any clinical value in detecting upper urinary tract TCC.
早期研究表明，巴德膀胱肿瘤抗原（BTA）检测对诊断膀胱移行细胞癌（TCC）有用。然而，该检测在上尿路TCC中的效用尚未得到评估。因此，我们评估了BTA检测在上尿路TCC中的临床效用。
我们对22例有TCC病史或临床怀疑有TCC的患者以及9例患有良性疾病的患者的71份输尿管和/或肾盂标本进行了检测。
与细胞学诊断相比，BTA的敏感性为65%，特异性为40%（与临床病史相关时），假阳性率为33%，假阴性率为62%。该检测的阳性预测值为83%，阴性预测值为32%。
BTA在上尿路TCC检测中没有任何临床价值。
